Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME family member 27 (PRAMEF27) is a predicted protein encoded by the PRAMEF27 gene in humans. It is thought to act as a substrate adaptor in ubiquitin-like ligase complexes, likely participating in the proteasome-mediated ubiquitin-dependent protein degradation pathway. PRAMEF27 is predicted to be a component of the Cul2-RING ubiquitin ligase complex and to function in the cytoplasm. There are currently no known direct associations of PRAMEF27 with specific diseases, nor are there known drugs targeting this protein. It is distinct from the more widely studied PRAME antigen (PReferentially expressed Antigen in Melanoma) and currently, there is no evidence supporting its role as a therapeutic target or as a biomarker in clinical contexts[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRAME family member 27 (PRAMEF27).